Assembly Biosciences Inc.

4.28-0.0500-1.15%Vol 518.17K1Y Perf -74.46%
Apr 16th, 2021 16:00 DELAYED
BID4.28 ASK4.30
Open4.37 Previous Close4.33
Pre-Market- After-Market4.28
 - -  - -%
Target Price
11.00 
Analyst Rating
Strong Buy 1.00
Potential %
157.01 
Finscreener Ranking
★★★★★     62.16
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★+     60.20
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★     61.74
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap171.45M 
Earnings Rating
Sell
Price Range Ratio 52W %
0.72 
Earnings Date
6th May 2021

Today's Price Range

4.224.38

52W Range

4.1127.84

5 Year PE Ratio Range

-7.70-6.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.83%
1 Month
-15.25%
3 Months
-30.18%
6 Months
-72.60%
1 Year
-74.46%
3 Years
-91.00%
5 Years
-17.53%
10 Years
-94.10%

TickerPriceChg.Chg.%
ASMB4.28-0.0500-1.15
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
8.90
9.20
0.03
0.04
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-65.00
-64.40
-
-43.73
RevenueValueIndustryS&P 500US Markets
75.02M
1.87
77.86
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.90-1.11-23.33
Q03 2020-0.78-0.0988.46
Q02 2020-0.030.19733.33
Q01 2020-0.98-0.7622.45
Q04 2019-1.01-0.991.98
Q03 2019-0.93-0.96-3.23
Q02 2019-1.10-0.7234.55
Q01 2019-1.07-1.051.87
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.79-3.95Negative
6/2021 QR-0.7712.50Positive
12/2021 FY-3.208.83Positive
12/2022 FY-2.96-10.45Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.79
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume518.17K
Shares Outstanding40.06M
Trades Count4.32K
Dollar Volume11.91M
Avg. Volume1.23M
Avg. Weekly Volume681.77K
Avg. Monthly Volume857.90K
Avg. Quarterly Volume1.33M

Assembly Biosciences Inc. (NASDAQ: ASMB) stock closed at 4.28 per share at the end of the most recent trading day (a -1.15% change compared to the prior day closing price) with a volume of 519.28K shares and market capitalization of 171.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 120 people. Assembly Biosciences Inc. CEO is John G. McHutchison.

The one-year performance of Assembly Biosciences Inc. stock is -74.46%, while year-to-date (YTD) performance is -29.26%. ASMB stock has a five-year performance of -17.53%. Its 52-week range is between 4.11 and 27.84, which gives ASMB stock a 52-week price range ratio of 0.72%

Assembly Biosciences Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 0.73, a price-to-sale (PS) ratio of 2.27, a price to cashflow ratio of 414.90, a PEG ratio of 2.32, a ROA of -19.03%, a ROC of -23.52% and a ROE of -23.10%. The company’s profit margin is -43.73%, its EBITDA margin is -64.40%, and its revenue ttm is $75.02 Million , which makes it $1.87 revenue per share.

Of the last four earnings reports from Assembly Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.79 for the next earnings report. Assembly Biosciences Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Assembly Biosciences Inc. is Strong Buy (1), with a target price of $11, which is +157.01% compared to the current price. The earnings rating for Assembly Biosciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Assembly Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Assembly Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.91, ATR14 : 0.30, CCI20 : -92.27, Chaikin Money Flow : -0.26, MACD : -0.44, Money Flow Index : 35.04, ROC : -4.89, RSI : 38.62, STOCH (14,3) : 31.58, STOCH RSI : 0.74, UO : 52.43, Williams %R : -68.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Assembly Biosciences Inc. in the last 12-months were: Jacqueline S. Papkoff (Sold 1 297 shares of value $7 983 ), John G. McHutchison (Sold 12 151 shares of value $264 917 ), Luisa M. Stamm (Sold 4 397 shares of value $22 404 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

CEO: John G. McHutchison

Telephone: +1 833 509-4583

Address: 331 Oyster Point Blvd, South San Francisco 94080, CA, US

Number of employees: 120

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

63%38%

Bearish Bullish

53%47%

Bearish Bullish

53%47%

News

Stocktwits